10q10k10q10k.net
Alkermes plc.

Alkermes plc.ALKSEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.

Top Holders

Holder% OwnedSharesChangeAs of
BlackRock, Inc.18.00%
30.0M
—2024-01-08
The Vanguard Group11.52%
19.0M
flat2024-11-12
T. ROWE PRICE ASSOCIATES, INC.7.90%
13.0M
—2024-11-14
Wellington Management Group LLP7.69%
12.7M
▼ -1.44pp2024-11-08
STATE STREET CORPORATION5.60%
1.6K
—2024-01-24
Sarissa Capital Management LP5.00%
8.3M
—2023-08-24

Insider Transactions

Net 90d: −$1.16M · buys $0 / sells $1.16M
Range:
Action:
Role:
InsiderRoleAction
2026-04-11Nancy LurkerDirectorOption exercise
3.8K
——
2026-04-06Gaffin David JosephEVP, CLO, Alkermes, Inc.Sell (open market)
2.0K
$34.57$70.3K
2026-04-01Hopkinson Craig C.EVP R&D, Chief Medical OfficerOption exercise
5.0K
$19.34$96.7K
2026-04-01Hopkinson Craig C.EVP R&D, Chief Medical OfficerSell (open market)
9.0K
$35.51$319.6K
2026-03-03Gaffin David JosephEVP, CLO, Alkermes, Inc.Sell (open market)
2.0K
$29.76$60.5K
2026-03-02Nichols Christian ToddSVP, Chief Commercial OfficerSell (open market)
6.0K
$30.00$180.0K
2026-03-02Hopkinson Craig C.EVP R&D, Chief Medical OfficerOption exercise
5.0K
$19.34$96.7K
2026-03-02Hopkinson Craig C.EVP R&D, Chief Medical OfficerSell (open market)
9.0K
$29.72$267.5K
2026-03-02Gaffin David JosephEVP, CLO, Alkermes, Inc.Sell (open market)
2.0K
$29.29$59.6K
2026-03-02Parisi Samuel JosephVP, Finance (Interim PAO)Sell (open market)
6.9K
$29.29$201.8K
1–10 of 35
Page 1 / 4